We've published our #RadiationOncology facilities report for New Zealand✍
It reveals a need to grow New Zealand’s radiation oncologist workforce and provide extra investment for cancer care equipment.
Read the report👉 https://t.co/FaBWQx1hTi
#RANZCR
Time to act to create a World Radiotherapy Awareness Day (week).
Use the QR code or link to register your support & get involved.
Spread the word to your networks.
https://t.co/bXIYY9kq12
WE NEED EVERYONE 🌏🌎🌍
Some fantastic presentations at ASTRO this year!
On the sheets:
RTOG 1112 HCC
RTOG 1005 SIB breast
MSKCC prophylactic palliation
RTOG 1270/ N107C central review
CURB, LUSTER for NSCLC & breast oligomets
EXTEND prostate oligoprog mets
SCLC dose escalation
LDR v HDR prostate
NRG/RTOG 1005 - concurrent versus sequential boost #ASTRO22 for breast #radiotherapy. Concurrent boost is non-inferior. No difference in QoL. Concordance with IMPORT High results. This patient-centric trial will save time for patients with #breastcancer. #bcsm#oncoalert
I am now "special" - as are my new podcast and two associated important articles.
@SalmaJabbour1@Mat_Guc@drdavidpalma
Podcast, oligomet part 1: https://t.co/zc33T8qHK1
ESTRO/EORTC classification: https://t.co/LcRAqXSuGB
SABR-COMET 5 yr outcomes:
https://t.co/zZQw0K565J
📢 Just out! 📢
@ClinOncology#LungCancer Special Edition. Hopefully topic and timely overviews and a provocative paper on UK Lung Cancer Outcomes.
👏 thanks to all the Authors, Editorial Team, Co-Ed @HattonMQF , but huge thanks to Co-Ed @KamalThippu 🙏 for his central role
Malignant Spinal Cord Compression (MSCC)- A Thread 🧵
Old fashioned medical tools of history and clinical examination are the key
Trust your instincts with this diagnosis
For those attending #ASTRO22, there’s an opportunity to reflect, revive, and reimagine just a few days later on the other side of the world. #radonc https://t.co/KF0oxjxn83